DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Mahon FX, Réa D, Guilhot J. et al.
Discontinuation of imatinib in patients
with chronic myeloid leukaemia who have maintained complete molecular
remission for at least 2 years: the prospective, multicentre Stop
Imatinib (STIM) trial.
Lancet Oncol 2010; 11: 1029-1035
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.